Drug intelligence / Profile preview

vaccinium myrtillus

Development stage
Unknown
Modality
Small Molecules
Administration
Oral, Topical
01

Overview

Vaccinium myrtillus is a plant species in the Ericaceae family, commonly known as bilberry or European blueberry. The parts used medicinally include both the fruit and the leaves. Bilberry leaves and fruits are rich in polyphenols and anthocyanins, with other significant phytochemicals like hydroxycinnamic acids, flavanols, flavonols, tannins, triterpenes, and phytosterols. Mechanistically, it exhibits antimicrobial, antioxidant, anti-inflammatory, vasoprotective, and antidiabetic effects relating primarily to its phenolic and flavonoid content, which modulate pathways related to inflammation, oxidative stress, microvascular integrity, and bacterial adhesion. Traditionally, bilberry leaves are used for diabetes management, while the fruit is indicated for vision problems (e.g., retinopathy, cataracts, macular degeneration, night-blindness), venous insufficiency, diarrhea, and capillary fragility. The mechanisms of antimicrobial action include inhibition of bacterial cell wall adhesion, disruption of membrane integrity, and synergistic interactions with some antibiotics. The fruit is marketed as a standardized herbal medicine in Europe, and both leaf and fruit extracts feature as dietary supplements. There is no recognized pharmaceutical developer; primary indications are for eye health, venous disorders, and diabetes. Safety concerns are minimal, with rare allergic reactions and theoretical interactions with anticoagulants described[1][2][3][4][5][6].

Other names
bilberryeuropean blueberrymyrtilli foliumblueberrymyrtillus
02

Targets

NOS2 (Nitric Oxide Synthase 2)IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on vaccinium myrtillus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on vaccinium myrtillus.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call